Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - March 25, 2026
Predicted Liver Safety of GlyphAgo, a Lymphatic targeting Prodrug of Agomelatine That Avoids First-pass Metabolism
SPTX Positive Sentiment
Predicted Liver Safety of GlyphAgo, a Lymphatic targeting Prodrug of Agomelatine That Avoids First-pass Metabolism
Key Takeaway: The article discusses GlyphAgo, a prodrug of Agomelatine designed to target lymphatics and enhance liver safety by avoiding first-pass metabolism. This innovative approach may lead to better therapeutic outcomes compared to traditional methods. The development of GlyphAgo is a significant advancement in drug formulation.
Market Sentiment Analysis
POSITIVE FACTORS
- GlyphAgo shows promise in liver safety.
- The prodrug avoids first-pass metabolism.
- Potential for improved therapeutic outcomes.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Frequently Asked Questions
What is GlyphAgo?
GlyphAgo is a prodrug of Agomelatine designed to target lymphatics.
How does GlyphAgo improve liver safety?
It avoids first-pass metabolism, enhancing liver safety.
What are the benefits of GlyphAgo?
It may lead to better therapeutic outcomes in treatment.